**Cholesterol-Lowering Injection Repatha Shows Significant Reduction in Cardiovascular Events**
*New Orleans* — A cholesterol-lowering injection that has been available for nearly a decade has now demonstrated its effectiveness in reducing cardiovascular events among individuals considered at high risk, even if they have not yet experienced a heart attack or stroke.
A recent study published in the *New England Journal of Medicine* and presented at the American Heart Association’s scientific sessions revealed that Repatha, developed by Amgen, can significantly cut the risk of coronary heart disease death, heart attack, and stroke.
The clinical trial, known as VESALIUS-CV, found that Repatha reduced these events by 25% overall. Notably, it lowered the incidence of first heart attacks by 36% in people with high cholesterol but no prior history of such serious cardiovascular problems. All participants were already taking statins or other cholesterol-lowering medications due to their elevated cholesterol levels.
In addition to reducing cardiovascular issues, Repatha also helped prevent the need for stent and bypass procedures, effectively meeting both primary endpoints of the trial. These results position Repatha as a more effective option than statin therapy, the older class of cholesterol-lowering drugs that have been the best-selling medicines worldwide.
This advancement offers new hope for patients at high risk of heart disease, emphasizing the potential benefits of incorporating Repatha into their treatment plans.
https://www.statnews.com/2025/11/08/amgen-repatha-heart-attack-risk-study-results/